Two Hospitals in the System - Sentara Heart Hospital and Sentara Virginia
Beach General Hospital will use SPY routinely
TORONTO, April 8 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging and image guidance systems for the operating room, today announced that Sentara Heart Hospital(R) in Norfolk, Virginia and Sentara Virginia Beach General Hospital in Virginia Beach, Virginia have fully integrated the SPY(R) Imaging System into its cardiac surgical programs as a routine quality measure and standard of care. Sentara has purchased three SPY Systems for its cardiac operating rooms, where the systems are being used by six cardiac surgeons performing more than 1200 coronary bypass procedures annually.. Sentara's cardiac surgical services rank among the top cardiac programs in the nation and specifically ranks among the top three based upon the key quality metric, "mortality ratio", according to the 2007 America's Best Hospitals Edition of U.S. News & World Report magazine.
"SPY is a perfect fit for Sentara as we are totally committed to continually furthering safety and the quality of care for all heart surgery patients," said Mary Blunt, Corporate Vice President and Administrator at Sentara Norfolk General Hospital.
"Based on our experience to date, we believe that SPY has great potential to positively impact both the immediate and long term outcomes of bypass surgery and therefore be accepted as a care standard, not just at our hospital, but by all hospitals performing bypass surgery," said Dr. Lenox Baker, Sentara's Chief of Cardiac Surgery.
The SPY System is the only fluorescent imaging system that enables cardiac surgeons to simply and efficiently visually assess the quality and function of their bypass grafts while the patient is still in the operating room. Use of the SPY system may allow surgeons to make intra-operative decisions that may optimize procedures for each individual patient. Clinical studies have shown that SPY can reduce serious complications that can be a result of bypass surgery such as graft failure and post-operative myocardial injury.
"As cardiac surgeons at Sentara, my colleagues and I are focused on performing the best possible bypass surgeries and to ensuring we have completely revascularized the heart" says Dr. Wayne Derkac of Mid Atlantic Cardiothoracic Surgeons, Ltd. "SPY quickly gives us high quality real-time images of each of our grafts, which we can use to first validate that our grafts are functioning properly and then demonstrate the success of the operation to ourselves, our team, our referral colleagues and most importantly, to our patients and their families".
"Upon meeting with Drs. Baker and Derkac and the team at Sentara, I am extremely impressed with their vision for healthcare in the United States and particularly impressed with their relentless pursuit to improve quality of care that has the potential to better long term patient outcomes and may also reduce expensive complications," said Dr. Arun Menawat, President and Chief Executive Officer of Novadaq Technologies Inc.. "As leaders in the field of cardiac surgery, they will set another standard through the use of SPY which we fully expect other surgeons and hospitals will follow."
About Novadaq Technologies
Novadaq Technologies Inc. commercializes real-time imaging and image guidance systems for use in the operating room. With one set of proprietary core technologies, Novadaq's products have multiple applications. Novadaq's SPY System enables cardiac surgeons to diagnose intra-operatively by visually assessing coronary vasculature and bypass graft functionality during the course of heart bypass surgery. The SPY System is also indicated for use during other surgeries, such as cardiovascular, plastic, reconstructive, organ transplant and urological procedures. SPY can be used to visualize blood vessels, tumors, tumor margins and the lymphatic system. Novadaq introduced PINPOINT(TM), its first minimally invasive imaging system for autofluorescence in October 2007. PINPOINT allows surgeons to differentiate between healthy and cancerous tissue in the lung and other hollow organs. Further expanding its portfolio of minimally invasive products, Novadaq is developing SPYscope which combines the typical features of a standard endoscope with the additional capabilities of SPY imaging. Novadaq is the exclusive United States distributor of PLC Medical's CO2 HEART LASER System, used in the same cardiac procedures as the SPY System. Novadaq also offers the OPTTX(R) System, which leverages the company's core imaging technology and is designed for the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD). For more information, please visit the company's website at http://www.novadaq.com.
Forward looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, results of future clinical tests of PINPOINT and the SPY System, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
|SOURCE Novadaq Technologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved